Poster Session: Hepatobiliary, Neuroendocrine/Carcinoid, Pancreatic & other GI Cancer
Hepatobiliary Cancer: Go to 78 Presentations
Neuroendocrine/Carcinoid: Go to 14 Presentations
Pancreatic Cancer: Go to 66 Presentations
Choice of four posters:
- Nanoliposomal irinotecan-based chemotherapy after regular irinotecan-based chemotherapy in patients with pancreas cancer.
Caleb J Smith, Tanios S. Bekaii-Saab, Kathryn Cook, et al.
Authors conclusion: Nal-IRI might be considered in pancreas cancer patients who had received regular irinotecan, particularly in the absence of disease progression with the latter.
- Efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin after progression on conventional irinotecan-containing chemotherapy for metastatic pancreatic adenocarcinoma.
Kyunghye Bang, Jaekyung Cheon, Jae Ho Jeong, et al.
Authors conclusion: Nal-IRI + 5-FU/LV showed only modest efficacy for mPAC patients who progressed on conventional irinotecan-containing chemotherapy. Cumulative dose of prior conventional irinotecan may be correlated with the efficacy of nal-IRI + 5-FU/LV.
- Real-world one-year overall survival among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan in the NAPOLI-1 based regimen.
George P. Kim, Paul Cockrum, Andy Surinach, Laith I. Abushahin
Authors conclusion: In this real-world cohort of patients with mPDAC treated with liposomal irinotecan, as expected, one-year OS increased as patients remained on therapy. Patients in this cohort were older, had more prior lines of therapy, worse ECOG PS, and similar exposure to treatment compared with patients in the registrational phase 3 NAPOLI-1 study. Among patients who received at least 4 cycles of liposomal irinotecan, one-year OS (29%) was similar to both the intent-to-treat (25%) and per protocol treated patient populations in the NAPOLI-1 trial (34%). Further studies are needed to understand the predictors of long-term survival among patients with mPDAC.
Other GI Cancer: Go to 23 Presentations